CD70

Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal

Retrieved on: 
Wednesday, April 13, 2022
Treatment, S.A, FTD, Cancer, Association, Twitter, Cancer research, Private Securities Litigation Reform Act, Renal cell carcinoma, GLOBE, Glioblastoma, RCC, Patient, Cell, Allogenes, Multiple myeloma, LinkedIn, T-cell lymphoma, Development, Kite Pharma, B-cell lymphoma, Nasdaq, Research and development, CD70, AML, CAR, Hematological Cancer Research Investment and Education Act, SEC, Forward-looking statement, American Association for Cancer Research, Neoplasm, Safety, TCR, American Association, FDA, Disease, AACR, Acute myeloid leukemia, Therapy, Pharmaceutical industry, Vaccine, Cellectis, Research

The findings were also published in Cancer Research, a journal of the American Association for Cancer Research.

Key Points: 
  • The findings were also published in Cancer Research, a journal of the American Association for Cancer Research.
  • CD70 has previously been shown to be highly expressed in RCC and several hematological cancers with limited normal tissue expression.
  • Multiple CAR T cell constructs were evaluated for anti-tumor activity against RCC cell line and patient-derived mouse tumor models.
  • AlloCAR T are trademarks ofAllogene Therapeutics, Inc.
    TALEN is a registered trademark of Cellectis, S.A.
    Allogenes AlloCAR T programs utilize Cellectis technologies.

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
BCMA, Elisa's, RCC, Private Securities Litigation Reform Act, Therapy, Adenocarcinoma, Sale, Gene expression, CD38, AML, CD70, Pharmacokinetics, Patient, IHC, Culture, Survival rate, CAR, AACR, SEC, Doctor of Philosophy, Serum, CRISPR Therapeutics, Antigen, Cryopreservation, American Association, Cancer, Renal cell carcinoma, ELISA, TGF, MDS, Immune system, RNA-Seq, MHC, Association, American Association for Cancer Research, NKG2D, Gene editing, Multiple myeloma, CBLB, Lymphatic system, COVID-19, Intellectual property, GLOBE, HCC, NK, SAN, CRISPR, Flow cytometry, Engineering, Escape Room, CD138, Vaccine, CISH

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022.
  • Posters are available for download on the Nkarta website ( https://www.nkartatx.com/publications/ ) and on the AACR e-poster website ( https://cattendee.abstractsonline.com/meeting/10517 ).
  • Editing targets included cytokine inducible SH2-containing protein (CISH) and the E3 ubiquitin ligase CBLB, both negative regulators of NK cell function.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell immunotherapies for cancer patients.

TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 22, 2022
Private Securities Litigation Reform Act, Cell, Therapy, Investment, D, Investigational New Drug, CD70, Clinical trial, Patient, IND, AACR, Risk, Research, Pathology, American Association, Cancer, TCR, Food, Poster, PD-1, Arbor, LLC, Lists of diseases, Association, Safety, Review, US Foods, Nasdaq, COVID-19, Data, GLOBE, Truc, U.S. Securities and Exchange Commission, HLA, Bristol Myers Squibb, Annual report, FDA, CRISPR, Biotechnology, American Association for Cancer Research, CD28, Partnership, Pharmaceutical industry, Vaccine, Video game

Net cash used in operations was $23.3 million for the fourth quarter of 2021 compared to $13.5 million for the fourth quarter of 2020.

Key Points: 
  • Net cash used in operations was $23.3 million for the fourth quarter of 2021 compared to $13.5 million for the fourth quarter of 2020.
  • R&D Expenses: Research and development expenses were $22.4 million for the fourth quarter of 2021 compared to $14.3 million for the fourth quarter of 2020.
  • G&A Expenses: General and administrative expenses were $5.2 million for the fourth quarter of 2021 compared to $4.3 million for the fourth quarter of 2020.
  • Net Loss: Net loss was $27.7 million for the fourth quarter of 2021 compared to $18.5 million for the fourth quarter of 2020.

Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, March 17, 2022
ClinicalTrials.gov, B-ALL, Private Securities Litigation Reform Act, Method, Therapy, CGMP, Acute myeloid leukemia, Degenerative disease, Sale, Investment, D, Cyclophosphamide, Diagnosis, CD70, Society, Clinical trial, NHL, Cash, CAR, ODD, SEC, Immunotherapy, Research, CRISPR Therapeutics, CISH, Cryopreservation, Patient, Cancer, CEO, Food, U.S. Securities and Exchange Commission, Chronic lymphocytic leukemia, MDS, Genome, G&A, NKG2D, Technology, Safety, Acute lymphoblastic leukemia, CLL, Microdeletion syndrome, CD19, COVID-19, Intellectual property, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, SITC, Society for Immunotherapy of Cancer, R, NK, FDA, CRISPR, Disease, Security (finance), Pharmaceutical industry, Vaccine, Fine chemical, Lithium, AML

R&D Expenses: Research and development (R&D) expenses were $63.4 million for the full year 2021 and $17.3 million for the fourth quarter of 2021.

Key Points: 
  • R&D Expenses: Research and development (R&D) expenses were $63.4 million for the full year 2021 and $17.3 million for the fourth quarter of 2021.
  • Non-cash stock-based compensation expense included in R&D expense was $6.7 million for the full year 2021 and $1.7 million for the fourth quarter of 2021.
  • G&A Expenses: General and administrative (G&A) expenses were $23.0 million for the full year 2021 and $5.6 million for the fourth quarter of 2021.
  • Non-cash stock-based compensation expense included in G&A expense was $7.7 million for the full year 2021 and $2.0 million for the fourth quarter of 2021.

Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma

Retrieved on: 
Thursday, March 10, 2022
Allogenes, Nasdaq, Safety, Research and development, Development, Twitter, Private Securities Litigation Reform Act, FTD, Neoplasm, Lymphatic system, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, CAR, Squamous cell carcinoma, Forward-looking statement, CD70, GLOBE, Patient, Review, Kite Pharma, Therapy, Disease, SEC, RCC, Food, Fast Track, SAN, LinkedIn, Vaccine, Pharmaceutical industry, Research, Cellectis

The FDA granted FTD based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinomas (RCC) who have failed standard RCC therapies.

Key Points: 
  • The FDA granted FTD based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinomas (RCC) who have failed standard RCC therapies.
  • Allogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
  • AlloCAR T is a trademark of Allogene Therapeutics, Inc.
    Allogenes AlloCAR T programs utilize Cellectis technologies.
  • The anti-CD70 AlloCAR T programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these AlloCAR T programs.

ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, March 8, 2022
Genetics, Safety, Molecular biology, MMAE, AACR, LDS, University of Texas Southwestern Medical Center, American Association for Cancer Research, University, Drug development, Daiichi Sankyo, Therapy, DARS, Cancer, Non-Hodgkin lymphoma, Lymphoma, PD, Celgene, Peking University, Rockefeller University, Mab, Merck, CD70, National university, Ovarian cancer, RATS, Trastuzumab, Therapeutic index, Doctor of Philosophy, LD, Patient, Renal cell carcinoma, American Association, Technology, Biology, Drug discovery, Benchmarking, Control, PK, Association, HER2, ADC, NSCLC, Fine chemical, Pharmaceutical industry, Vaccine, Pharmacology, Biochemistry

"These presentations at the AACR annual meeting will demonstrate the continued and rapid advancement of our lead programs as well as the potential of our ADC technology.

Key Points: 
  • "These presentations at the AACR annual meeting will demonstrate the continued and rapid advancement of our lead programs as well as the potential of our ADC technology.
  • I look forward to bringing these programs to clinical trials to help patients with cancer."
  • ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
  • Built on innovative technology platforms, ProfoundBio has developed a pipeline consisting of multiple solid tumor-targeting drug candidates that are currently in discovery and preclinical development stages.

Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA

Retrieved on: 
Tuesday, February 15, 2022
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, NYSE, Patient, ADC, Form, Food, CEO, SEC, Forward-looking statement, File, Private Securities Litigation Reform Act, IND, Multiple myeloma, Acute myeloid leukemia, Immune system, Goal, Clinical trial, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Cytokine, Drug discovery, Renal cell carcinoma, Neoplasm, Therapure BioPharma Inc, U.S. Securities and Exchange Commission, FDA, Board, CD70, Pharmacokinetics, Clear cell renal cell carcinoma, Control, COVID-19, SEC filing, Trial of the century, Pharmaceutical industry

ARX305 is the third ADC developed by Ambrx on its proprietary Engineered Precision Biologics platform that has received IND clearance.

Key Points: 
  • ARX305 is the third ADC developed by Ambrx on its proprietary Engineered Precision Biologics platform that has received IND clearance.
  • Ambrx previously licensed the rights to develop and commercialize ARX305 in China to NovoCodex Pharmaceuticals Ltd. (NovoCodex).
  • Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics.
  • In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology.

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Retrieved on: 
Monday, January 10, 2022
Forward-looking statement, Patient, Technology, Research, Securities & Exchange Commission of Pakistan, BCMA, CD70, LinkedIn, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Multiple myeloma, MM, CEO, GLOBE, AML, Acute myeloid leukemia, Euronext Growth, Abnormality, B-cell lymphoma, Chromosome, CAR, Gene editing, YouTube, Degenerative disease, Cancer, Food, U.S. Securities and Exchange Commission, Annual report, Acute lymphoblastic leukemia, FDA, Euronext, B-ALL, Social media, Pharmaceutical industry, Vaccine, Nasdaq, Cellectis

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced that the U.S. Food and Drug Administration (FDA) has lifted the hold on its clinical trials.

Key Points: 
  • The FDA had placed a clinical hold on all five of Allogenes clinical trials on October 7, 2021 following a report of a chromosomal abnormality detected in ALLO-501A CAR+ T-cells from a single patient enrolled in Allogenes ALPHA2 study.
  • Allogene reported today that the investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogenes manufacturing process and had no clinical significance.
  • We are very pleased that our licensed partner Allogene is now able to resume its clinical trials, bringing us one step closer to delivering these innovative therapies to patients with unmet medical needs, said Dr. Andr Choulika, CEO of Cellectis.
  • TALEN gene editing technologies were not involved in the findings leading to the clinical hold.

Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials

Retrieved on: 
Monday, January 10, 2022
SEC, Cellectis, SAN, Telephone, LinkedIn, Investor, Cancer, Patient, CAR, Gene editing, DLL3, ID, Research and development, Forward-looking statement, Abnormality, Kite Pharma, FLT3, Partnership, Food, CD70, Review, Therapy, Development, Private Securities Litigation Reform Act, Company, BCMA, News, Nasdaq, Chromosome, International, FDA, Twitter, Webcast, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Vaccine, Research, Allogenes

Investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogenes manufacturing process and had no clinical significance.

Key Points: 
  • Investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogenes manufacturing process and had no clinical significance.
  • Allogene will be working with clinical trial investigators to resume study activities across AlloCAR T development programs as quickly as possible.
  • Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at BCMA, FLT3, DLL3 and CD70.
  • AlloCAR T is a trademark of Allogene Therapeutics, Inc.
    TALEN is a registered trademark of Cellectis S.A.

Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 7, 2022
Biotechnology, Pharmaceutical, Health, Actinium, Yttrium-90, COVID-19, Food, Ibritumomab tiuxetan, Receptor (biochemistry), Growth, Therapy, Technology, Astellas Pharma, Patient, Radionuclide, AstraZeneca, Cancer, Control, Daiichi Sankyo, NorthStar, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Application, Monoclonal antibody, FDA, Bristol Myers Squibb, Partnership, Pfizer, Radioimmunotherapy, Seagen, Neutralizing antibody, CD70, ADC, Vaccine, Generic drug, Fine chemical, Enfortumab vedotin

The "Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The conjugated monoclonal antibodies market consists of the sales of conjugated monoclonal antibodies.
  • The high cost of conjugated monoclonal antibodies is anticipated to limit the growth of the conjugated monoclonal antibodies market.
  • Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships for developing new conjugated monoclonal antibodies shaping the market.